EUVIMEDEUVIMED entdecken
Crossref

Activity of the novel oral antimicrobials zoliflodacin and gepotidacin against ceftriaxone-resistant and/or multidrug-resistant Neisseria gonorrhoeae isolates from Hangzhou, China

Wenyan Lu, Ying Fu, Xu'ai Lin, Yuefeng Rao, Magnus Unemo, Stijn van der Veen iD

Journal of Antimicrobial Chemotherapy · 01.09.2026 · 81 (10)

DOI: 10.1093/jac/dkag330 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 29.09.2026. Verfasst von Wenyan Lu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases of the Second Affiliated Hospital of Zhejiang University School of Medicine, Department of Microbiology, School of …. Hauptthemen laut MEDLINE: Neisseria gonorrhoeae, Anti-Bacterial Agents, Drug Resistance, Multiple, Bacterial, Barbiturates. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Zhejiang Province Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The emergence of ceftriaxone-resistant Neisseria gonorrhoeae threatens the effectiveness of this last-line empirical therapy for gonorrhoea. Zoliflodacin and gepotidacin are novel oral gyrase/topoisomerase inhibitors with distinct mechanisms of action, recently US FDA-approved for treatment of uncomplicated urogenital gonorrhoea. We evaluated their in vitro activity against contemporary multidrug-resistant N. gonorrhoeae isolates from Hangzhou, China, a region with high ceftriaxone resistance.

Methods

MICs of zoliflodacin and gepotidacin were determined by agar dilution for 340 clinical N. gonorrhoeae isolates collected in Hangzhou (2020–2025). Sequencing of gyrA, parC and gyrB quinolone resistance-determining regions (QRDRs) was performed.

Results

All isolates were ciprofloxacin-resistant, and 23.2% were ceftriaxone-resistant. Zoliflodacin demonstrated potent activity (MIC range, 0.008–0.25 mg/L; MIC90, 0.06 mg/L). No isolate carried known GyrB target substitutions associated with increased zoliflodacin MICs (in D429 or K450), but GyrA S91F/D95G with ParC S87R was associated with slightly higher zoliflodacin wild-type MICs (P = 0.0004). Gepotidacin MICs ranged from 0.06 mg/L to 4 mg/L (MIC90, 2 mg/L); 42 isolates (12.4%) had non-susceptible MICs ≥2 mg/L. GyrA S91F/D95Y with ParC S87N and GyrA S91F/D95A with ParC D86N were associated with slightly higher gepotidacin MICs (P < 0.0001). No Spearman's rank correlation was observed between ciprofloxacin and zoliflodacin (R = 0.059) or gepotidacin (R = 0.0077) MICs.

Conclusions

Zoliflodacin demonstrated potent in vitro activity and all isolates in this high-ceftriaxone-resistance setting were categorized as susceptible. Gepotidacin also showed potent activity, but 12% of isolates displayed non-susceptible MICs (≥2 mg/L). Continuous surveillance (phenotypic and genomic susceptibility) is essential when these two novel oral therapies enter clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neisseria gonorrhoeaeAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialBarbituratesGonorrheaCeftriaxoneSpiro CompoundsAcenaphthenesMicrobial Sensitivity TestsChinaHumansDNA GyraseThird Generation CephalosporinsHeterocyclic Compounds, 3-RingIsoxazolesMorpholinesOxazolidinones

Substanzen

Anti-Bacterial AgentszoliflodacingepotidacinBarbituratesCeftriaxoneSpiro CompoundsAcenaphthenesDNA GyraseThird Generation CephalosporinsHeterocyclic Compounds, 3-Ring

Autor:innen und Institutionen

  • Department of Infectious Diseases of the Second Affiliated Hospital of Zhejiang University School of Medicine, Department of Microbiology, School of Medicine, Zhejiang University, Hangzhou, China.
  • Department of Clinical Laboratory, Sir Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
  • Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • WHO Collaborating Centre for Gonorrhoea and Other STIs, National Reference Laboratory for Sexually Transmitted Infections, Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sw…
  • Institute for Global Health, University College London (UCL), London, UK.
  • State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

ORCID-Profile: Stijn van der Veen

Förderung

  • National Natural Science Foundation of China
  • Zhejiang Province Natural Science Foundation

Zitieren

APA

Lu, W., Fu, Y., Lin, X., Rao, Y., Unemo, M., & van der Veen, S. (2026). Activity of the novel oral antimicrobials zoliflodacin and gepotidacin against ceftriaxone-resistant and/or multidrug-resistant Neisseria gonorrhoeae isolates from Hangzhou, China. Journal of Antimicrobial Chemotherapy, 81(10). https://doi.org/10.1093/jac/dkag330

Vancouver

Lu W, Fu Y, Lin X, Rao Y, Unemo M, van der Veen S. Activity of the novel oral antimicrobials zoliflodacin and gepotidacin against ceftriaxone-resistant and/or multidrug-resistant Neisseria gonorrhoeae isolates from Hangzhou, China. Journal of Antimicrobial Chemotherapy. 2026;81(10). doi:10.1093/jac/dkag330

BibTeX
@article{Lu2026,
  author = {Lu, Wenyan and Fu, Ying and Lin, Xu'ai and Rao, Yuefeng and Unemo, Magnus and van der Veen, Stijn},
  title = {Activity of the novel oral antimicrobials zoliflodacin and gepotidacin against ceftriaxone-resistant and/or multidrug-resistant Neisseria gonorrhoeae isolates from Hangzhou, China},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {10},
  doi = {10.1093/jac/dkag330}
}
Kostenlos starten →